Ipsen’s statements and announcements

Key highlights

Ipsen and Medetia join forces to accelerate early research in rare disease

– 06 June 2023 – 0 mins read

06 June 2023 – 0 mins read

Ipsen and Medetia join forces to accelerate early research in rare disease

testing

Filter

Topics

Period

Filter by

Reset

Showing: 1 – 05 of 6 Media Statements

Show

Sort

An update for healthcare professionals and patients on Increlex® (mecasermin) Injection

– 03 October 2024

03 October 2024

An update for healthcare professionals and patients on Increlex® (mecasermin) Injection

Testing statements summary

Ipsen announces sale of Priority Review Voucher for $158m

– 27 August 2024

27 August 2024

Ipsen announces sale of Priority Review Voucher for $158m

PARIS, FRANCE, 27 August 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) has entered into an agreement to sell its rare pediatric disease Priority Review Voucher (PRV) to a large global pharmaceutical company. Ipsen received the PRV coinciding with the SohonosTM…

– 29 July 2024

29 July 2024

Testing video 1

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type…

– 06 June 2023

06 June 2023

Ipsen and Medetia join forces to accelerate early research in rare disease

testing

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

– 24 April 2023

24 April 2023

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

Ipsen is committed to bringing innovative medicines to the rare disease community where a significant unmet need exists and innovation in treatments is lacking.